Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Loss of the tumor suppressor BAP1 causes myeloid transformation.

Dey A, Seshasayee D, Noubade R, French DM, Liu J, Chaurushiya MS, Kirkpatrick DS, Pham VC, Lill JR, Bakalarski CE, Wu J, Phu L, Katavolos P, LaFave LM, Abdel-Wahab O, Modrusan Z, Seshagiri S, Dong K, Lin Z, Balazs M, Suriben R, Newton K, Hymowitz S, Garcia-Manero G, Martin F, Levine RL, Dixit VM.

Science. 2012 Sep 21;337(6101):1541-6. Epub 2012 Aug 9.

2.

Cancer. Emerging anatomy of the BAP1 tumor suppressor system.

White AE, Harper JW.

Science. 2012 Sep 21;337(6101):1463-4. No abstract available.

PMID:
22997315
3.

Loss of BAP1 function leads to EZH2-dependent transformation.

LaFave LM, Béguelin W, Koche R, Teater M, Spitzer B, Chramiec A, Papalexi E, Keller MD, Hricik T, Konstantinoff K, Micol JB, Durham B, Knutson SK, Campbell JE, Blum G, Shi X, Doud EH, Krivtsov AV, Chung YR, Khodos I, de Stanchina E, Ouerfelli O, Adusumilli PS, Thomas PM, Kelleher NL, Luo M, Keilhack H, Abdel-Wahab O, Melnick A, Armstrong SA, Levine RL.

Nat Med. 2015 Nov;21(11):1344-9. doi: 10.1038/nm.3947. Epub 2015 Oct 5.

4.

The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression.

Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J, Sui G, Hart GW, Rauscher FJ 3rd, Drobetsky E, Milot E, Shi Y, Affar el B.

Mol Cell Biol. 2010 Nov;30(21):5071-85. doi: 10.1128/MCB.00396-10. Epub 2010 Aug 30.

5.

The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer.

Daou S, Hammond-Martel I, Mashtalir N, Barbour H, Gagnon J, Iannantuono NV, Nkwe NS, Motorina A, Pak H, Yu H, Wurtele H, Milot E, Mallette FA, Carbone M, Affar el B.

J Biol Chem. 2015 Nov 27;290(48):28643-63. doi: 10.1074/jbc.M115.661553. Epub 2015 Sep 28.

6.

Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.

Balasubramani A, Larjo A, Bassein JA, Chang X, Hastie RB, Togher SM, Lähdesmäki H, Rao A.

Nat Commun. 2015 Jun 22;6:7307. doi: 10.1038/ncomms8307.

7.

BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma.

Matatall KA, Agapova OA, Onken MD, Worley LA, Bowcock AM, Harbour JW.

BMC Cancer. 2013 Aug 5;13:371. doi: 10.1186/1471-2407-13-371.

8.

An emerging model for BAP1's role in regulating cell cycle progression.

Eletr ZM, Wilkinson KD.

Cell Biochem Biophys. 2011 Jun;60(1-2):3-11. doi: 10.1007/s12013-011-9184-6. Review.

9.

The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.

Abdel-Wahab O, Dey A.

Leukemia. 2013 Jan;27(1):10-5. doi: 10.1038/leu.2012.288. Epub 2012 Oct 9. Review.

PMID:
23147254
10.

Retracted: Histone H2B ubquitination regulates retinoic acid signaling through the cooperation of ASXL1 and BAP1.

Lee SW, Youn H, Kim EJ, Um SJ.

Mol Cell. 2013 Jul 25;51(2):200-10. doi: 10.1016/j.molcel.2013.06.005. Epub 2013 Jul 11. Retraction in: Mol Cell. 2013 Aug 22;51(4):552.

11.

[Role of ASXL1 mutation in myeloid malignancies].

Sheng MY, Zhou Y, Xu MJ, Yang FC.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Aug;22(4):1183-7. doi: 10.7534/j.issn.1009-2137.2014.04.057. Review. Chinese.

PMID:
25130853
12.

Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.

Kadariya Y, Cheung M, Xu J, Pei J, Sementino E, Menges CW, Cai KQ, Rauscher FJ, Klein-Szanto AJ, Testa JR.

Cancer Res. 2016 May 1;76(9):2836-44. doi: 10.1158/0008-5472.CAN-15-3371. Epub 2016 Feb 19.

13.

The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1.

Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A.

J Biol Chem. 2009 Dec 4;284(49):34179-88. doi: 10.1074/jbc.M109.046755. Epub 2009 Oct 8.

14.

Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.

Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave LM, Koche R, Shih AH, Guryanova OA, Kim E, Li S, Pandey S, Shin JY, Telis L, Liu J, Bhatt PK, Monette S, Zhao X, Mason CE, Park CY, Bernstein BE, Aifantis I, Levine RL.

J Exp Med. 2013 Nov 18;210(12):2641-59. doi: 10.1084/jem.20131141. Epub 2013 Nov 11.

15.

BAP1/ASXL1 recruitment and activation for H2A deubiquitination.

Sahtoe DD, van Dijk WJ, Ekkebus R, Ovaa H, Sixma TK.

Nat Commun. 2016 Jan 7;7:10292. doi: 10.1038/ncomms10292.

16.

Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.

Togo Y, Yoshikawa Y, Suzuki T, Nakano Y, Kanematsu A, Zozumi M, Nojima M, Hirota S, Yamamoto S, Hashimoto-Tamaoki T.

Int J Oncol. 2016 Apr;48(4):1571-80. doi: 10.3892/ijo.2016.3395. Epub 2016 Feb 17.

PMID:
26891804
17.

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.

Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL.

Cancer Cell. 2012 Aug 14;22(2):180-93. doi: 10.1016/j.ccr.2012.06.032.

18.

Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.

Wang J, Li Z, He Y, Pan F, Chen S, Rhodes S, Nguyen L, Yuan J, Jiang L, Yang X, Weeks O, Liu Z, Zhou J, Ni H, Cai CL, Xu M, Yang FC.

Blood. 2014 Jan 23;123(4):541-53. doi: 10.1182/blood-2013-05-500272. Epub 2013 Nov 19.

19.

Suppressive role of OGT-mediated O-GlcNAcylation of BAP1 in retinoic acid signaling.

Moon S, Lee YK, Lee SW, Um SJ.

Biochem Biophys Res Commun. 2017 Oct 7;492(1):89-95. doi: 10.1016/j.bbrc.2017.08.029. Epub 2017 Aug 10.

PMID:
28802580
20.

ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.

Valletta S, Dolatshad H, Bartenstein M, Yip BH, Bello E, Gordon S, Yu Y, Shaw J, Roy S, Scifo L, Schuh A, Pellagatti A, Fulga TA, Verma A, Boultwood J.

Oncotarget. 2015 Dec 29;6(42):44061-71. doi: 10.18632/oncotarget.6392.

Supplemental Content

Support Center